Skip to main content

Advertisement

SpringerLink
Log in

Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We studied the serum levels of B cell survival factors BAFF and APRIL in patients with idiopathic inflammatory myositis (IIM) and their relation with clinical and autoantibodies. Seventy-five patients (51 females and 24 males) with IIM (Bohan and Peter’s criteria 1975) and 25 healthy adults were analyzed for BAFF, APRIL and IL-17 by ELISA, and myositis-specific and associated antibodies (MSA and MAA) using line immunoblot assay. Of the 75 patients, 59 were adults, 42 had Dermatomyositis (DM), and 17 had Polymyositis. Median disease duration was 5 (3–12) months. BAFF levels were higher in IIM than healthy controls [p = 0.001], and in children with jDM than adults [p = 0.026]. BAFF levels were higher in adults with arthritis [p = 0.018], weight loss [p = 0.007], and PAH [p = 0.004]. Among the various MSAs, lowest levels were seen in those with anti-SRP [p = 0.043]. Median follow-up duration was 145 patient years. Twelve patients relapsed, while nine were in drug-free remission. BAFF were similar between these groups. Serum APRIL levels were elevated in limited number of patients with myositis, and the levels did not differ amongst the clinico-serologic phenotypes. IL-17 levels were higher in individuals positive for anti-SRP [p = 0.028]. Serum BAFF levels are elevated in IIM, more so in children. BAFF levels may be useful as biomarker for PAH and arthritis. Anti-SRP positivity is associated with elevated IL-17 levels suggesting role in pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41:22–26

    Article  CAS  Google Scholar 

  2. Lundberg IE, Forbess CJ (2008) Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 26:S109–S114

    CAS  PubMed  Google Scholar 

  3. Lundberg IE, Miller FW, Tjärnlund A, Bottai M (2016) Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 280:39–51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM (2009) Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 60:1160–1172

    Article  PubMed  Google Scholar 

  5. Salajegheh M, Pinkus JL, Amato AA, Morehouse C, Jallal B, Yao Y, Greenberg SA (2010) Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 42:576–583

    Article  PubMed  Google Scholar 

  6. McIntyre D, Zuckerman NS, Field M, Mehr R, Stott DI (2014) The V(H) repertoire and clonal diversification of B cells in inflammatory myopathies. Eur J Immunol 44:585–596

    Article  CAS  PubMed  Google Scholar 

  7. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, and the RIM Study Group (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O (2015) Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One 10:e0133702

    Article  PubMed  PubMed Central  Google Scholar 

  9. Morais SA, Vilas-Boas A, Isenberg DA (2015) B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 7:122–151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol 190:291–292

    Article  CAS  PubMed  Google Scholar 

  11. Baek A, Park HJ, Na S-J, Shim DS, Moon J-S, Yang Y, Choi YC (2012) The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 249:96–100

    Article  CAS  PubMed  Google Scholar 

  12. Kryštůfková O, Barbasso Helmers S, Venalis P, Malmström V, Lindroos E, Vencovský J et al (2014) Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther 16:454

    Article  PubMed  PubMed Central  Google Scholar 

  13. Peng Q-L, Shu X-M, Wang D-X, Wang Y, Lu X, Wang G-C (2014) B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med 8:395–403

    Article  CAS  PubMed  Google Scholar 

  14. Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23

    Article  CAS  PubMed  Google Scholar 

  15. Srivastava P, Dwivedi S, Misra R (2016) Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int 36:935–943

    Article  CAS  PubMed  Google Scholar 

  16. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49–54

    Article  CAS  Google Scholar 

  17. Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T, Agematsu K, Yokota S, Koike K (2015) Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol 42:2412–2418

    Article  CAS  PubMed  Google Scholar 

  18. Tournadre A, Miossec P (2009) Chemokines and dendritic cells in inflammatory myopathies. Ann Rheum Dis 68:300–304

    Article  CAS  PubMed  Google Scholar 

  19. Tournadre A, Lenief V, Miossec P (2010) Expression of toll-like receptor 3 and toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 62:2144–2151

    CAS  PubMed  Google Scholar 

  20. Hengstman GJD, ter Laak HJ, Vree Egberts WTM, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BGM (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, Koch A, Heppner FL, Stenzel W (2012) Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 181:2161–2171

    Article  PubMed  Google Scholar 

  22. Chevrel G, Granet C, Miossec P (2005) Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappa B nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 64:1257–1262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kocić J, Santibañez JF, Krstić A, Mojsilović S, Dorđević IO, Trivanović D et al (2012) Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2. Biochim Biophys Acta 1823:838–849

    Article  PubMed  Google Scholar 

  24. Kocić J, Santibañez JF, Krstić A, Mojsilović S, Ilić V, Bugarski D (2013) Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase. Int J Biochem Cell Biol 45:464–475

    Article  PubMed  Google Scholar 

  25. Moura RA, Quaresma C, Vieira AR, Gonçalves MJ, Polido-Pereira J, Romão VC et al B-cell phenotype and IgD-CD27-memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PloS One 12:e0182927

  26. Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J et al (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68:836–843

    Article  PubMed  Google Scholar 

  27. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192–201

    Article  CAS  PubMed  Google Scholar 

  28. Gupta L, Ahmed S, Zanwar A (2017) The pathogenesis of scleroderma. Indian J Rheumatol 12:142

    Article  Google Scholar 

  29. Campi I, Tosi D, Rossi S, Vannucchi G, Covelli D, Colombo F et al. (2015) B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases. Thyroid Off J Am Thyroid Assoc 25:1043–1049

    Article  CAS  Google Scholar 

  30. López De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS et al (2013) BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol 40:294–302

    Article  PubMed  Google Scholar 

  31. Bassyouni IH, Azab NA, El-Dakrony E-HM, Fawzi MMT, Ghanoum R, Bassyouni RH. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: possible association with myositis? Jt Bone Spine Rev Rhum 2011;78:56–61

Download references

Funding

The work was supported by Intramural research grant to RNM.

Author information

Authors and Affiliations

  1. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226014, India

    Latika Gupta, Smriti Chaurasia, Puja Srivastava, Sanjay Dwivedi, Able Lawrence & Ramnath Misra

Authors
  1. Latika Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Smriti Chaurasia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Puja Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sanjay Dwivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Able Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ramnath Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramnath Misra.

Ethics declarations

Disclosures

None.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, L., Chaurasia, S., Srivastava, P. et al. Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults. Clin Rheumatol 37, 1265–1271 (2018). https://doi.org/10.1007/s10067-018-4046-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4046-x

Keywords

Search

Navigation